Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.

Date publication

décembre 2014

Journal

BMC cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie

Tous les auteurs :
Borget I, Pérol M, Pérol D, Lavolé A, Greillier L, Dô P, Westeel V, Crequit J, Léna H, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Chabaud S, Vergnenegre A, Zalcman G, Chouaïd C,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/25511923

Résumé

The IFCT-GFPC 0502 phase III study reported prolongation of progression-free survival with gemcitabine or erlotinib maintenance vs. observation after cisplatin-gemcitabine induction chemotherapy for advanced non-small-cell lung cancer (NSCLC). This analysis was undertaken to assess the incremental cost-effectiveness ratio (ICER) of these strategies for the global population and pre-specified subgroups.

Mots clés

Adult, Aged, Antineoplastic Agents, administration & dosage, Carcinoma, Non-Small-Cell Lung, drug therapy, Cisplatin, administration & dosage, Cost-Benefit Analysis, Deoxycytidine, administration & dosage, Erlotinib Hydrochloride, Female, Health Care Costs, Humans, Induction Chemotherapy, economics, Lung Neoplasms, drug therapy, Maintenance Chemotherapy, economics, Male, Middle Aged, Prospective Studies, Quality-Adjusted Life Years, Quinazolines, administration & dosage, Survival Analysis

Référence

BMC Cancer. 2014 Dec;14:953